Physician profile
Watson Payne Roye
NPI 1013932466
$5,582.83
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $782 · 2020: $45.73 · 2021: $3,343 · 2022: $89.86 · 2023: $152 · 2024: $1,170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,013 · Food and Beverage: $310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,012.50 |
| Food and Beverage | $309.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,853.43 | 2019-2024 | Da Vinci Surgical System |
| Boston Scientific Corporation | $1,146.15 | 2024 | Apollo Esg System |
| Covidien LP | $226.28 | 2019 | |
| Ethicon US, LLC | $106.21 | 2019-2023 | Echelon Flex |
| Heron Therapeutics, INC. | $61.14 | 2023 | Aponvie |
| Medtronic, INC. | $39.72 | 2022-2023 | Interstim |
| Integra Lifesciences Corporation | $38.05 | 2021 | |
| Allergan, INC. | $26.35 | 2022 | |
| Becton, Dickinson and Company | $17.94 | 2021 | |
| W. L. Gore & Associates, INC. | $17.18 | 2023 | Gore Enform Preperitoneal Biomaterial |
| Smith+Nephew, INC. | $16.55 | 2020 | |
| Myriad Genetic Laboratories, INC. | $14.05 | 2021 | |
| Stryker Corporation | $13.41 | 2022 | |
| Reprise Biomedical, INC. | $6.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Watson Roye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.